Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate carbidopa, primarily focusing on Parkinson's disease—including idiopathic and advanced forms—as well as major depressive disorder, nonarteritic anterior ischemic optic neuropathy, and healthy volunteers. Encompassing completed, recruiting, terminated, and withdrawn studies, these evaluations examine diverse modalities including subcutaneous infusions and intestinal gels. Prominent academic and industry sponsors leading these trials include AbbVie, NeuroDerm Ltd., UCB Pharma, Shanghai WD Pharmaceutical, and Charité University Berlin.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07151378 | RECRUITING | PARKINSON DISEASE (Disorder) |
University Hospital Tuebingen |
2025-10-27 | PHASE3 |
| NCT06013956 | RECRUITING | Parkinson Disease |
David Escobar |
2023-08-29 | PHASE4 |
| NCT05285683 | RECRUITING | Chronic Pain |
University of Rochester |
2024-01-31 | PHASE2 |
| NCT04246437 | RECRUITING | Autonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy; Dementia With Lewy Bodies |
Daniel Claassen |
2020-02-04 | PHASE1 |
| NCT06075771 | RECRUITING | Anhedonia; Depression |
Emory University |
2023-11-21 | PHASE4 |
| NCT06785298 | RECRUITING | Parkinson Disease |
Tanta University |
2024-12-10 | PHASE2; PHASE3 |
| NCT07229664 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-10 | PHASE2; PHASE3 |
| NCT07229651 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-10 | PHASE2; PHASE3 |
| NCT07246278 | RECRUITING | Parkinson Disease |
Tanta University |
2025-11-20 | PHASE1; PHASE2 |
| NCT06113640 | RECRUITING | Parkinson Disease |
Mostafa Bahaa |
2023-11-05 | PHASE2; PHASE3 |
| NCT06831500 | RECRUITING | Multi-system Atrophy - Parkinsonian Type; Orthostatic Hypotension, Dysautonomic; Parkinson Disease |
Julien Bally |
2025-07-18 | PHASE1; PHASE2 |
| NCT05909267 | RECRUITING | Depressive Disorder, Major |
Charite University, Berlin, Germany |
2023-07-26 | |
| NCT04520178 | RECRUITING | Spinal Cord Injuries |
University of Alberta |
2020-07-01 | PHASE2; PHASE3 |
| NCT07442591 | RECRUITING | Healhty |
Shanghai WD Pharmaceutical Co., Ltd. |
2026-03-24 | PHASE1 |
| NCT07001150 | RECRUITING | Parkinson Disease |
Tanta University |
2025-05-10 | PHASE2 |
| NCT06765668 | RECRUITING | Parkinson Disease |
Impax Laboratories, LLC |
2025-02-12 | PHASE4 |
| NCT06596876 | COMPLETED | Parkinson's Disease |
Jiangsu HengRui Medicine Co., Ltd. |
2024-11-06 | PHASE3 |
| NCT05471609 | COMPLETED | Healthy Volunteers |
University of Minnesota |
2025-06-12 | EARLY_PHASE1 |
| NCT05463367 | ACTIVE_NOT_RECRUITING | Opioid Use; Opioid Dependence; Opioid-use Disorder; Narcotic Use; Back Pain; Back Injuries; Chronic Pain; Chronic Low-back Pain; Pain, Chronic; Pain;Back Low;Chronic; Pain, Back |
Northwestern University |
2021-01-01 | PHASE2 |
| NCT06587217 | COMPLETED | Parkinsonian Signs in Older Persons |
University of Michigan |
2024-10-29 | PHASE1; PHASE2 |
| NCT05781711 | COMPLETED | Parkinson Disease |
Tanta University |
2023-01-06 | PHASE2 |
| NCT06115538 | UNKNOWN | Parkinson Disease; Treatment Adherence |
Ankara Ataturk Sanatorium Training and Research Hospital |
2023-10-01 | PHASE4 |
| NCT05962957 | COMPLETED | Parkinson Disease |
Mostafa Bahaa |
2023-08-07 | PHASE2 |
| NCT03735901 | ACTIVE_NOT_RECRUITING | Acute Stroke; Stroke Rehabilitation |
University Hospital, Basel, Switzerland |
2019-06-14 | PHASE3 |
| NCT06236230 | UNKNOWN | Parkinson Disease |
Second Affiliated Hospital of Soochow University |
2023-11-15 | PHASE4 |
| NCT06219915 | COMPLETED | Parkinsonian Signs in Older Persons |
University of Michigan |
2024-03-15 | PHASE1; PHASE2 |
| NCT04821830 | COMPLETED | Parkinson Disease |
University of Michigan |
2020-02-12 | PHASE4 |
| NCT06614153 | COMPLETED | Parkinson's Disease |
Jiangsu HengRui Medicine Co., Ltd. |
2023-05-16 | PHASE2 |
| NCT06180720 | UNKNOWN | Healthy |
The Affiliated Hospital of Qingdao University |
2023-12-20 | PHASE1 |
| NCT06432309 | COMPLETED | Parkinson Disease; Effect of Drug |
University Hospital of Ferrara |
2022-07-01 | |
| NCT04952194 | UNKNOWN | Parkinson Disease |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-01-01 | PHASE4 |
| NCT05087914 | WITHDRAWN | Acute Pain; Bunionectomy; Toe Fusion |
Northwestern University |
2021-11-01 | PHASE2 |
| NCT06161220 | COMPLETED | Cardiac Repolarization in Healthy Subjects |
Impax Laboratories, LLC |
2023-10-30 | PHASE1 |
| NCT04723147 | COMPLETED | Depression; Anhedonia |
Emory University |
2021-01-29 | PHASE4 |
| NCT04052776 | COMPLETED | Spinal Cord Injuries; Drug Effect |
Centre Hospitalier Universitaire Vaudois |
2020-09-11 | PHASE1 |
| NCT05976737 | UNKNOWN | Healthy |
The Affiliated Hospital of Qingdao University |
2023-08-17 | PHASE1 |
| NCT04742348 | WITHDRAWN | Alcohol Drinking |
University of Washington |
2023-02 | PHASE4 |
| NCT05909267 | Recruiting | Depressive Disorder Major |
Charite University Berlin Germany|Prof. Dr. Stefan M. Gold|Prof. Dr. Soyoung Q Park|Dr. Ulrike Grittner|Motognosis GmbH |
2023-07-26 | Not Applicable |
| NCT04000919 | SUSPENDED | Spinal Cord Injuries |
Jessica M D'Amico |
2019-06-19 | PHASE2; PHASE3 |
| NCT05094050 | COMPLETED | Parkinson's Disease |
AbbVie |
2022-01-18 | PHASE1 |
| NCT05036473 | COMPLETED | Parkinson Disease |
Shanghai WD Pharmaceutical Co., Ltd. |
2021-11-11 | PHASE2 |
| NCT04082715 | WITHDRAWN | Chronic Back Pain |
Second Affiliated Hospital of Wenzhou Medical University |
2019-10 | PHASE2 |
| NCT05083260 | COMPLETED | Parkinson Disease |
BioVie Inc. |
2022-01-04 | PHASE1; PHASE2 |
| NCT04778176 | COMPLETED | Parkinson's Disease |
SynAgile Corporation |
2021-06-16 | PHASE2 |
| NCT03929068 | COMPLETED | Amyotrophic Lateral Sclerosis; Motor Neuron Disease |
Washington University School of Medicine |
2019-05-13 | PHASE1 |
| NCT04325503 | COMPLETED | Parkinsonian Signs in Older Persons |
University of Michigan |
2021-02-08 | PHASE1; PHASE2 |
| NCT05250141 | COMPLETED | Bioequivalence |
Laboratorios Andromaco S.A. |
2022-02-14 | PHASE1 |
| NCT05094050 | Completed | Parkinson''s Disease |
AbbVie |
2022-01-18 | Phase 1 |
| NCT04590612 | UNKNOWN | Parkinson Disease; Depression |
Western University, Canada |
2021-01 | |
| NCT04650217 | TERMINATED | Depressive Disorder |
New York State Psychiatric Institute |
2021-10-07 | PHASE4 |
| NCT05128175 | COMPLETED | Parkinson Disease |
Shanghai WD Pharmaceutical Co., Ltd. |
2021-10-29 | PHASE1 |
| NCT02480803 | COMPLETED | Parkinson's Disease |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-12-19 | PHASE4 |
| NCT00660673 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2009-11-13 | PHASE3 |
| NCT04493320 | TERMINATED | Depression; Cognitive Impairment; Gait Impairment |
New York State Psychiatric Institute |
2021-02-10 | PHASE4 |
| NCT05128175 | Unknown status | Parkinson Disease |
Shanghai WD Pharmaceutical Co. Ltd. |
2021-10-29 | Phase 1 |
| NCT04380142 | COMPLETED | Parkinson's Disease (PD) |
AbbVie |
2020-10-19 | PHASE3 |
| NCT03670953 | COMPLETED | Parkinson's Disease (Disorder) |
Impax Laboratories, LLC |
2018-11-06 | PHASE3 |
| NCT04591535 | UNKNOWN | Parkinson Disease |
Hong Kong WD Pharmaceutical Co., Limited |
2020-09-28 | PHASE1 |
| NCT02873351 | WITHDRAWN | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2019-09 | PHASE2 |
| NCT04513340 | UNKNOWN | Parkinson Disease |
Hong Kong WD Pharmaceutical Co., Limited |
2020-08-13 | PHASE1 |
| NCT03266965 | COMPLETED | Multiple Sclerosis |
University of Miami |
2018-03-23 | PHASE1 |
| NCT03197493 | COMPLETED | Macula; Degeneration; Retina |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-08-01 | PHASE2 |
| NCT00685919 | COMPLETED | Postural Tachycardia Syndrome; Orthostatic Intolerance |
Vanderbilt University |
2008-05 | PHASE2; PHASE3 |
| NCT02549092 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2015-10-26 | PHASE3 |
| NCT03023059 | COMPLETED | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-05-02 | PHASE2 |
| NCT02513485 | COMPLETED | Depression |
Emory University |
2015-10-09 | PHASE4 |
| NCT03022318 | COMPLETED | Age-related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2017-05-02 | PHASE2 |
| NCT02615873 | UNKNOWN | Parkinson's Disease |
Intec Pharma Ltd. |
2016-07 | PHASE3 |
| NCT03451500 | TERMINATED | Age Related Macular Degeneration |
Snyder, Robert W., M.D., Ph.D., P.C. |
2018-07-01 | PHASE2 |
| NCT02799381 | COMPLETED | Parkinson's Disease (PD) |
AbbVie |
2017-02-09 | PHASE3 |
| NCT04236921 | COMPLETED | Other |
Riverside Pharmacueticals Corporation |
2019-07-15 | PHASE1 |
| NCT02726386 | ACTIVE_NOT_RECRUITING | Parkinson's Disease |
NeuroDerm Ltd. |
2016-05-04 | PHASE2 |
| NCT03761004 | COMPLETED | Healthy Volunteers |
Hong Kong WD Pharmaceutical Co., Limited |
2019-01-14 | PHASE1 |
| NCT02605434 | UNKNOWN | Parkinson's Disease |
Intec Pharma Ltd. |
2016-03 | PHASE3 |
| NCT03887884 | COMPLETED | Parkinson's Disease |
Acorda Therapeutics |
2019-03-05 | PHASE1 |
| NCT03541356 | COMPLETED | Parkinson's Disease |
Impel Pharmaceuticals |
2018-05-08 | PHASE2 |
| NCT02553265 | COMPLETED | Dysautonomia, Familial; Baroreflex Failure Syndrome |
NYU Langone Health |
2015-09 | PHASE2 |
| NCT03235037 | COMPLETED | Angelman Syndrome |
Bennett Lavenstein |
2013-11-26 | |
| NCT03576638 | UNKNOWN | Parkinson Disease |
Intec Pharma Ltd. |
2018-07 | PHASE2 |
| NCT03115827 | COMPLETED | Parkinson Disease |
Vanderbilt University Medical Center |
2017-04-18 | PHASE4 |
| NCT03462043 | WITHDRAWN | Parkinson |
NeuroDerm Ltd. |
2018-04-10 | PHASE3 |
| NCT03496870 | COMPLETED | Parkinson Disease |
Neurocrine Biosciences |
2018-02-08 | PHASE1 |
| NCT01663935 | TERMINATED | Albinism; Oculocutaneous Albinism |
University of Wisconsin, Madison |
2012-10-17 | PHASE2 |
| NCT01951105 | COMPLETED | Sub-acute Back Pain |
Northwestern University |
2015-02-24 | PHASE4 |
| NCT03140956 | COMPLETED | Parkinson Disease |
Orion Corporation, Orion Pharma |
2017-04-19 | PHASE1 |
| NCT03055936 | COMPLETED | Healthy Volunteers |
Orion Corporation, Orion Pharma |
2017-02-21 | PHASE1 |
| NCT02837640 | UNKNOWN | Retinitis Pigmentosa |
Beirut Eye Specialist Hospital |
2016-06 | PHASE2 |
| NCT02452606 | UNKNOWN | Parkinson Disease; Sleep Disorders |
Asan Medical Center |
2015-03 | |
| NCT02346630 | WITHDRAWN | Stroke |
Ross D. Zafonte, MD |
2015-03 | PHASE4 |
| NCT01393457 | COMPLETED | Cocaine Dependence |
The University of Texas Health Science Center, Houston |
2011-06 | PHASE2 |
| NCT02080819 | COMPLETED | Cocaine Dependence |
Virginia Commonwealth University |
2014-02 | PHASE2 |
| NCT00223691 | COMPLETED | Autonomic Failure; Orthostatic Hypotension |
Vanderbilt University |
2002-03 | PHASE1 |
| NCT00223717 | COMPLETED | Hypertension |
Vanderbilt University |
2001-01 | PHASE1 |
| NCT02577523 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2015-12-29 | PHASE2 |
| NCT00715520 | COMPLETED | Stroke |
Emory University |
2007-04 | |
| NCT02812394 | COMPLETED | Parkinson Disease |
Acorda Therapeutics |
2016-06 | PHASE1 |
| NCT02633839 | COMPLETED | Smoking |
Acorda Therapeutics |
2015-12 | PHASE1 |
| NCT02633007 | COMPLETED | Asthma |
Acorda Therapeutics |
2015-12 | PHASE1 |
| NCT01636037 | COMPLETED | Schizophrenia |
Centre for Addiction and Mental Health |
2012-09 | PHASE2 |
| NCT02554734 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2015-08 | PHASE1 |
| NCT02763137 | COMPLETED | Parkinson Disease |
IRCCS San Raffaele Roma |
2014-07-30 | PHASE2 |
| NCT02448914 | COMPLETED | Parkinson's Disease |
LobSor Pharmaceuticals AB |
2015-05 | PHASE1 |
| NCT02486432 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2015-04 | PHASE1 |
| NCT02096601 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2014-08-11 | PHASE1 |
| NCT01736176 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2013-03 | PHASE3 |
| NCT01960842 | COMPLETED | Advanced Parkinson's Disease |
AbbVie |
2013-10 | PHASE3 |
| NCT02312232 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2014-11 | PHASE1 |
| NCT01840423 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2013-05 | PHASE1 |
| NCT01683253 | COMPLETED | Impulse Control Disorder |
Sandoz |
2012-11 | PHASE4 |
| NCT01688089 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2012-09 | PHASE1 |
| NCT01468012 | COMPLETED | Cocaine Dependence |
New York State Psychiatric Institute |
2014-07 | PHASE2; PHASE3 |
| NCT02116465 | COMPLETED | Fasted State |
Desitin Arzneimittel GmbH |
2014-03 | PHASE1 |
| NCT01190813 | COMPLETED | Amblyopia |
Jaeb Center for Health Research |
2010-09 | PHASE3 |
| NCT01568073 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2011-03 | PHASE3 |
| NCT00547911 | TERMINATED | Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases |
National Institute of Neurological Disorders and Stroke (NINDS) |
2007-10 | PHASE1; PHASE2 |
| NCT01411137 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2011-08 | PHASE3 |
| NCT01725802 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2012-12-16 | PHASE1 |
| NCT01486628 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2012-04-30 | PHASE1 |
| NCT01617135 | COMPLETED | Idiopathic Parkinson's Disease |
Acorda Therapeutics |
2012-05 | PHASE2 |
| NCT00360568 | COMPLETED | Dyskinesias; Parkinson's Disease; Severe Motor Fluctuations |
AbbVie (prior sponsor, Abbott) |
2009-06 | PHASE3 |
| NCT00918177 | COMPLETED | Parkinson's Disease |
Intec Pharma Ltd. |
2009-07 | PHASE2 |
| NCT01515410 | COMPLETED | Parkinson's Disease; Motor Fluctuations |
Depomed |
2012-01 | PHASE2 |
| NCT01766258 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2011-05 | PHASE2 |
| NCT01528592 | COMPLETED | Parkinson's Disease |
Northwestern University |
2011-06 | |
| NCT01479127 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2011-10 | PHASE2 |
| NCT01227655 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2011-03 | PHASE3 |
| NCT01218425 | COMPLETED | Dopamine Activity; Episodic Memory Consolidation; Response Preparation |
Maastricht University Medical Center |
2010-11 | |
| NCT00335153 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2008-01 | PHASE3 |
| NCT01437293 | COMPLETED | Cocaine Abuse |
New York State Psychiatric Institute |
2010-08 | PHASE1 |
| NCT00218023 | COMPLETED | Cocaine Abuse; Cocaine-Related Disorders |
The University of Texas Health Science Center, Houston |
2006-03 | PHASE2 |
| NCT01429077 | COMPLETED | Nonfluent Aphasia; Stroke |
Shirley Ryan AbilityLab |
2007-10 | PHASE2; PHASE3 |
| NCT01212484 | COMPLETED | Familial Dysautonomia |
NYU Langone Health |
2009-12 | PHASE3 |
| NCT01130493 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2010-05 | PHASE3 |
| NCT02170376 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2011-09 | PHASE1 |
| NCT00713583 | COMPLETED | Cocaine Dependence |
The University of Texas Health Science Center, Houston |
2008-01 | PHASE2 |
| NCT01229332 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2011-01 | PHASE1; PHASE2 |
| NCT01323374 | COMPLETED | Fibromyalgia |
Chelsea Therapeutics |
2009-01 | PHASE2 |
| NCT00357994 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2009-01 | PHASE3 |
| NCT01171313 | COMPLETED | Parkinson's Disease |
XenoPort, Inc. |
2010-07 | PHASE2 |
| NCT00660387 | COMPLETED | Advanced Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2009-12 | PHASE3 |
| NCT01296464 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2011-02 | PHASE2 |
| NCT00983814 | COMPLETED | Attention Deficit Hyperactivity Disorder |
Chelsea Therapeutics |
2009-10 | PHASE2 |
| NCT01399905 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2009-03 | PHASE2 |
| NCT00141518 | COMPLETED | Advanced Idiopathic Parkinson's Disease |
AbbVie (prior sponsor, Abbott) |
2006-03 | PHASE4 |
| NCT01103011 | COMPLETED | Parkinson's Disease |
NeuroDerm Ltd. |
2010-04 | PHASE1 |
| NCT01484990 | COMPLETED | Parkinson Disease |
AbbVie |
2010-04 | PHASE1 |
| NCT02169414 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2010-02 | PHASE1 |
| NCT01568047 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2010-02 | PHASE2 |
| NCT00829439 | COMPLETED | Angelman Syndrome |
Boston Children's Hospital |
2009-01 | PHASE1 |
| NCT00845000 | COMPLETED | Parkinson Disease |
Merck Sharp & Dohme LLC |
2009-04-21 | PHASE1 |
| NCT01070628 | COMPLETED | Parkinson's Disease |
Orion Corporation, Orion Pharma |
2009-12 | PHASE1 |
| NCT01519284 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-11 | PHASE1 |
| NCT01568034 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2009-04 | PHASE2 |
| NCT00914602 | COMPLETED | Parkinson's Disease |
XenoPort, Inc. |
2009-05 | PHASE1; PHASE2 |
| NCT00601978 | WITHDRAWN | Parkinson's Disease |
Novartis Pharmaceuticals |
2008-08 | PHASE4 |
| NCT00906828 | COMPLETED | Parkinson Disease |
Uppsala University |
2008-10 | PHASE4 |
| NCT01533077 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-03 | PHASE1 |
| NCT00789672 | COMPLETED | Amblyopia |
Jaeb Center for Health Research |
2009-01 | PHASE2 |
| NCT01533116 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2009-03 | PHASE1 |
| NCT00869791 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2008-11 | PHASE2 |
| NCT00272688 | COMPLETED | Parkinson Disease |
University Hospital, Akershus |
2006-01 | PHASE4 |
| NCT00642356 | TERMINATED | Parkinson's Disease |
Novartis |
2008-03 | PHASE4 |
| NCT00125567 | COMPLETED | Idiopathic Parkinson's Disease |
Orion Corporation, Orion Pharma |
2005-08 | PHASE4 |
| NCT02169453 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2008-10 | PHASE1 |
| NCT02169479 | COMPLETED | Parkinson's Disease (PD) |
Bial - Portela C S.A. |
2008-09 | PHASE1 |
| NCT00558337 | COMPLETED | Parkinson's Disease |
Osmotica Pharmaceutical US LLC |
2007-11 | PHASE2 |
| NCT00099268 | COMPLETED | Parkinson's Disease |
Novartis Pharmaceuticals |
2004-09 | PHASE3 |
| NCT00590122 | COMPLETED | Parkinson's Disease |
Baylor College of Medicine |
2006-10 | PHASE4 |
| NCT00219284 | COMPLETED | Parkinson's Disease With End of Dose Wearing Off |
Novartis Pharmaceuticals |
2005-01 | PHASE4 |
| NCT00391898 | COMPLETED | Parkinson's Disease |
Novartis |
2006-10 | PHASE4 |
| NCT00888186 | COMPLETED | Parkinson Disease; Dyskinesias |
Uppsala University |
2008-02 | PHASE4 |
| NCT00693862 | COMPLETED | Pharmacokinetics |
Orion Corporation, Orion Pharma |
2006-12 | PHASE1 |
| NCT00505843 | COMPLETED | Parkinson's Disease |
Merck Sharp & Dohme LLC |
2007-05 | PHASE1 |
| NCT00562198 | TERMINATED | Parkinson´s Disease |
Orion Corporation, Orion Pharma |
2008-01 | PHASE2 |
| NCT00253084 | COMPLETED | Parkinson's Disease |
Impax Laboratories, LLC |
2005-11 | PHASE2 |
| NCT00218075 | COMPLETED | Cocaine Abuse; Cocaine-Related Disorders |
The University of Texas Health Science Center, Houston |
2000-03 | PHASE2 |
| NCT03103399 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2006-09-26 | PHASE2 |
| NCT00134966 | COMPLETED | Parkinson's Disease |
Novartis |
2005-08 | PHASE3 |
| NCT00129181 | COMPLETED | Parkinson Disease; Parkinsonian Syndrome |
Institute for Neurodegenerative Disorders |
2005-01 | |
| NCT00203177 | COMPLETED | Parkinson's Disease |
Teva Branded Pharmaceutical Products R&D, Inc. |
2001-10 | PHASE3 |
| NCT00143026 | COMPLETED | Parkinson's Disease |
Novartis |
2005-07 | PHASE4 |
| NCT02774564 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2005-09 | PHASE1 |
| NCT00199407 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2004-06 | PHASE3 |
| NCT00199420 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2004-07 | PHASE3 |
| NCT00203164 | COMPLETED | Parkinson's Disease |
Teva Branded Pharmaceutical Products R&D, Inc. |
2002-05 | PHASE3 |
| NCT03091868 | COMPLETED | Parkinson Disease |
Bial - Portela C S.A. |
2004-11-03 | PHASE1 |
| NCT00200447 | COMPLETED | Parkinson's Disease |
Molecular NeuroImaging |
2004-03 | PHASE2 |
| NCT00139867 | COMPLETED | Parkinson's Disease |
UCB Pharma |
2004-01 | PHASE3 |
| NCT00456794 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-03 | PHASE2 |
| NCT00955045 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-08 | PHASE2; PHASE3 |
| NCT00456586 | COMPLETED | Parkinson's Disease |
Kyowa Kirin, Inc. |
2002-04 | PHASE2 |
| NCT02763839 | COMPLETED | Parkinson's Disease |
Bial - Portela C S.A. |
2001-04 | PHASE1 |
| NCT00432393 | COMPLETED | Nonarteritic Anterior Ischemic Optic Neuropathy |
Shahid Beheshti University of Medical Sciences |
2002-06 | PHASE4 |
| NCT00415922 | COMPLETED | Healthy |
Novartis |
2006-07 | PHASE1 |
| NCT00174239 | TERMINATED | Parkinson Disease |
Pfizer |
2004-07 | PHASE4 |
| NCT00415844 | COMPLETED | Healthy |
Novartis |
2006-06 | PHASE1 |
| NCT00415831 | COMPLETED | Healthy |
Novartis |
2006-06 | PHASE1 |
| NCT00415740 | COMPLETED | Healthy |
Novartis |
2006-05 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-13)
Check the
Carbidopa
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.